VGH-TAYLOR: Comprehensive precision medicine study protocol on the heterogeneity of Taiwanese breast cancer patients-Reference-Cited by-全球学者库

VGH-TAYLOR: Comprehensive precision medicine study protocol on the heterogeneity of Taiwanese breast cancer patients

Published:2021-11 Issue:31 Volume:17 Page:4057-4069
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Liu Chun-Yu¹²³⁴,Huang Chi-Cheng³⁵⁶,Tsai Yi-Fang³⁴⁶,Chao Ta-Chung¹³⁴,Lien Pei-Ju³⁷,Lin Yen-Shu³⁶,Feng Chin-Jung³,Chen Ji-Lin³,Chen Yen-Jen³⁴⁶,Chiu Jen-Hwey³⁶⁸,Hsu Chih-Yi⁴⁹,Tseng Ling-Ming³⁴⁶¹⁰^ORCID

Affiliation:

1. Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan

2. Division of Transfusion Medicine, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

3. Comprehensive Breast Health Center, Taipei Veterans General Hospital, Taipei, Taiwan

4. School of Medicine, National Yang Ming Chiao Tung University, Hsinchu, Taiwan

5. Department of Public Health, College of Public Health, National Taiwan University, Taipei, Taiwan

6. Division of General Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan

7. Department of Nursing, Taipei Veterans General Hospital, Taipei, Taiwan

8. Institute of Traditional Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan

9. Department of Pathology & Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

10. Division of Experimental Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan

Abstract

Heterogeneity in breast cancer leads to diverse morphological features and different clinical outcomes. There are inherent differences in breast cancer between the populations in Asia and in western countries. The use of immune-based treatment in breast cancer is currently in the developmental stage. The VGH-TAYLOR study is designed to understand the genetic profiling of different subtypes of breast cancer in Taiwan and define the molecular risk factors for breast cancer recurrence. The T-cell receptor repertoire and the potential effects of immunotherapy in breast cancer subjects is evaluated. The favorable biomarkers for early detection of tumor recurrence, diagnosis and prognosis may provide clues for the selection of individualized treatment regimens and improvement in breast cancer therapy.

Funder

Yong-Lin Healthcare Foundation

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2021-0131

Reference46 articles.

1. Cancers in Taiwan: Practical insight from epidemiology, treatments, biomarkers, and cost

2. Epidemiology and survival outcome of breast cancer in a nationwide study

3. Breast cancer diagnosis: Imaging techniques and biochemical markers

4. Usefulness of Traditional Serum Biomarkers for Management of Breast Cancer Patients

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genomic Alterations of Tumors in HER2-Low Breast Cancers;International Journal of Molecular Sciences;2024-01-21

2. Prevalence of BRCA1, BRCA2, and PALB2 genomic alterations among 924 Taiwanese breast cancer assays with tumor-only targeted sequencing: extended data analysis from the VGH-TAYLOR study;Breast Cancer Research;2023-12-14

3. Prevalent landscape of tumor genomic alterations of luminal B1 breast cancers using a comprehensive genomic profiling assay in Taiwan;Breast Cancer;2023-12-09

4. Correlation of an immune-related 8-gene panel with pathologic response to neoadjuvant chemotherapy in patients with primary breast cancers;Translational Oncology;2023-12

5. Concordance of Targeted Sequencing from Circulating Tumor DNA and Paired Tumor Tissue for Early Breast Cancer;Cancers;2023-09-08